课题基金 / 基金详情

Pharmacist-guided, patient-driven management of high blood pressure in CKD: A Novel Approach

Pharmacist-guided, patient-driven management of high blood pressure in CKD: A Novel Approach
药剂师指导、以患者为主导的 CKD 高血压管理:一种新方法
批准号:
10535326
负责人:
Diana I Jalal
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-10-01 至 2026-09-30

项目摘要

项目成果

Diana I Jalal的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Background. Chronic kidney disease (CKD) associates with high morbidity and mortality due to CKD progression and cardiovascular disease (CVD). Blood pressure (BP) lowering reduces the risk of CVD and CKD progression. In spite of the large number of BP medications available, a significant proportion of Veterans with CKD have BP above the goal. The current practice involves licensed providers performing medication titrations to achieve BP goals and is associated with limited patient engagement. Our preliminary data indicate that the implementation of pharmacist-guided patient-driven titration of BP medications is effective and feasible in CKD. In this model, Veterans self-manage their BP medications under the guidance of the clinical pharmacist based on a pre-determined medication titration plan. Significance. The prevalence of CKD is extremely high among Veterans, with some studies reporting a prevalence of 47% (vs 11% in the general population). Here, we propose a novel interdisciplinary care model that engages the Veterans as an active participant in their care with the goal of improving BP control to improve long term outcomes. The application addresses a key HSR&D priority (management of complex chronic disease). Innovation and Impact. First, the proposed care model is one that has not been tested and includes the clinical pharmacist working with the provider and the Veterans so that Veterans with CKD can self-manage their hypertension. While self-management is exercised in CKD once patients are on dialysis (via home dialysis modalities), the self-management approach is not utilized in the earlier stages of CKD. Second, in the approach, we will utilize a transdisciplinary approach to evaluate the implementation of pharmacist-guided self- management of BP medications and we will apply constructs of an implementation science framework, Consolidated Framework for Implementation Research (CFIR), to understand Veteran and system factors that may either facilitate or impede the implementation and sustainment of the pharmacist-guided self-management approach. Specific aims. Specific aim 1 will evaluate if pharmacist-guided self-management of BP medications is more effective than self-monitoring of home BP + the standard care amongst Veterans with CKD. Specific aim 2 will identify and understand Veteran factors that may influence the acceptability of and the adherence to the self- management approach whereas specific aim 3 will focus on understanding system factors that may facilitate or impede the implementation of the self-management approach. Methods. One hundred and sixty Veterans with uncontrolled hypertension and either stage 2 CKD with albuminuria or stage 3 and 4 CKD will be randomized to either pharmacist-guided self-management or to self- monitoring + the standard practice for 12 months. Aim 1 will evaluate change in [standardized] office systolic BP at 12 months as the primary outcome. Aim 2 will utilize a mixed methods approach including semi- structured interviews to evaluate a sample of 20 Veterans in each of the study arms. We will further design data abstraction tools to evaluate the adherence to the intervention. In aim 3, we will utilize CFIR constructs to guide our qualitative semi-structured interviews with key organizational stakeholders including PACT clinical pharmacists, PCPs, and CKD providers (20 key stakeholders). Implementation. The PI will implement the pharmacist-guided self-management approach with the Pharmacy and Ambulatory care services as operational partners. The implementation of this approach will improve the patient experience (Survey of Healthcare Experiences of Patients) and the quality of care (Clinical Performance Measurement Program and the Strategic Analytics for Improvement and Learning).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD
  • 批准号:
    10657133
  • 项目类别:
  • 资助金额:
    $62.94万
  • 财政年份:
    2023
  • 负责人:
    Diana I Jalal
  • 依托单位:
Curcumin Supplementation for Improving Vascular and Cognitive Function
  • 批准号:
    9754868
  • 项目类别:
  • 资助金额:
    $56.47万
  • 财政年份:
    2017
  • 负责人:
    Diana I Jalal
  • 依托单位:
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD
  • 批准号:
    8535735
  • 项目类别:
  • 资助金额:
    $17.94万
  • 财政年份:
    2010
  • 负责人:
    Diana I Jalal
  • 依托单位:
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD
  • 批准号:
    8137219
  • 项目类别:
  • 资助金额:
    $17.94万
  • 财政年份:
    2010
  • 负责人:
    Diana I Jalal
  • 依托单位:
海外基金